FTY720 FREEDOMS data

Initial study results

Media release

English

 

Fact Sheets

FREEDOMS
(100 KB)

FTY720 (Oral Fingolimod)
(140 KB)

Multiple Sclerosis (MS)
(100 KB)

Novartis in MS
(100 KB)

 

IR Presentation

Trevor Mundel, Global Head of Development
Gordon Francis, Head Clinical Science Unit, NeuroImmunology

FTY720 FREEDOMS study: Initial results
(250 KB)

Webcast

Sep. 30, 2:00pm CET

 

The information in the press release and other materials was factually accurate on the date of publication. The press release and other materials remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.